Chronic myeloid leukemia

• Verfasst von: Hehlmann, Rüdiger [VerfasserIn]
• Verfasst von: Berger, Ute [VerfasserIn]
• Verfasst von: Hochhaus, Andreas [VerfasserIn]
• Titel: Chronic myeloid leukemia
• Titelzusatz: a model for oncology
• Verf.angabe: Rüdiger Hehlmann, Ute Berger, Andreas Hochhaus
• E-Jahr: 2005
• Jahr: 02 June 2005
• Umfang: 11 S.
• Fussnoten: Gesehen am 12.05.2022
• Titel Quelle: Enthalten in: Annals of hematology
• Ort Quelle: Berlin : Springer, 1991
• Jahr Quelle: 2005
• Band/Heft Quelle: 84(2005), 8, Seite 487-497
• ISSN Quelle: 1432-0584
• DOI: doi:10.1007/s00277-005-1039-z
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Chronic myeloid leukemia
• Sach-SW: Evolution to blast crisis
• Sach-SW: Imatinib in combination
• Sach-SW: Model for oncology
• Sach-SW: Targeted therapy
• K10plus-PPN: 1801658412

Abstract

Leukemias have traditionally served as model systems for research on neoplasia because of the easy availability of cell material from blood and marrow for diagnosis, monitoring and studies on pathophysiology. Beyond these more technical aspects, chronic myeloid leukemia (CML) became the first neoplasia in which the elucidation of the genotype led to a rationally designed therapy of the phenotype. Targeting of the pathogenetically relevant BCR-ABL tyrosine kinase with the selective kinase inhibitor imatinib has induced remissions with almost complete disappearance of any signs and symptoms of CML. This therapeutic success has triggered an intensive search for target structures in other cancers and has led to the development of numerous inhibitors of potential targets, which are being studied in preclinical and clinical trials worldwide. This review deals with some of the recent developments that have evolved since our last review in this journal in 2000 (Hehlmann R, Hochhaus A, Berger U, Reiter A (2000) Current trends in the management of chronic myelogenous leukemia. Ann Hematol 79:345-354).